These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 12171897

  • 1. Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer.
    Cassinelli G, Lanzi C, Supino R, Pratesi G, Zuco V, Laccabue D, Cuccuru G, Bombardelli E, Zunino F.
    Clin Cancer Res; 2002 Aug; 8(8):2647-54. PubMed ID: 12171897
    [Abstract] [Full Text] [Related]

  • 2. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
    Taraboletti G, Micheletti G, Rieppi M, Poli M, Turatto M, Rossi C, Borsotti P, Roccabianca P, Scanziani E, Nicoletti MI, Bombardelli E, Morazzoni P, Riva A, Giavazzi R.
    Clin Cancer Res; 2002 Apr; 8(4):1182-8. PubMed ID: 11948131
    [Abstract] [Full Text] [Related]

  • 3. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes.
    Cassinelli G, Supino R, Perego P, Polizzi D, Lanzi C, Pratesi G, Zunino F.
    Int J Cancer; 2001 Jun 01; 92(5):738-47. PubMed ID: 11340581
    [Abstract] [Full Text] [Related]

  • 4. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells.
    Ciardiello F, Caputo R, Borriello G, Del Bufalo D, Biroccio A, Zupi G, Bianco AR, Tortora G.
    Int J Cancer; 2002 Mar 20; 98(3):463-9. PubMed ID: 11920601
    [Abstract] [Full Text] [Related]

  • 5. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2.
    Fernandez A, Udagawa T, Schwesinger C, Beecken W, Achilles-Gerte E, McDonnell T, D'Amato R.
    J Natl Cancer Inst; 2001 Feb 07; 93(3):208-13. PubMed ID: 11158189
    [Abstract] [Full Text] [Related]

  • 6. Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells.
    Lanzi C, Cassinelli G, Cuccuru G, Supino R, Zuco V, Ferlini C, Scambia G, Zunino F.
    Prostate; 2001 Sep 15; 48(4):254-64. PubMed ID: 11536305
    [Abstract] [Full Text] [Related]

  • 7. Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft.
    Petrangolini G, Cassinelli G, Pratesi G, Tortoreto M, Favini E, Supino R, Lanzi C, Belluco S, Zunino F.
    Br J Cancer; 2004 Apr 05; 90(7):1464-8. PubMed ID: 15054472
    [Abstract] [Full Text] [Related]

  • 8. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.
    Vredenburg MR, Ojima I, Veith J, Pera P, Kee K, Cabral F, Sharma A, Kanter P, Greco WR, Bernacki RJ.
    J Natl Cancer Inst; 2001 Aug 15; 93(16):1234-45. PubMed ID: 11504769
    [Abstract] [Full Text] [Related]

  • 9. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines.
    Ling YH, Jiang JD, Holland JF, Perez-Soler R.
    Mol Pharmacol; 2002 Sep 15; 62(3):529-38. PubMed ID: 12181429
    [Abstract] [Full Text] [Related]

  • 10. Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis.
    Aranha O, Grignon R, Fernandes N, McDonnell TJ, Wood DP, Sarkar FH.
    Int J Oncol; 2003 Apr 15; 22(4):787-94. PubMed ID: 12632069
    [Abstract] [Full Text] [Related]

  • 11. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.
    Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler IJ.
    Clin Cancer Res; 2003 Mar 15; 9(3):1200-10. PubMed ID: 12631626
    [Abstract] [Full Text] [Related]

  • 12. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
    Tyagi AK, Singh RP, Agarwal C, Chan DC, Agarwal R.
    Clin Cancer Res; 2002 Nov 15; 8(11):3512-9. PubMed ID: 12429642
    [Abstract] [Full Text] [Related]

  • 13. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
    Tortora G, Caputo R, Damiano V, Caputo R, Troiani T, Veneziani BM, De Placido S, Bianco AR, Zangemeister-Wittke U, Ciardiello F.
    Clin Cancer Res; 2003 Feb 15; 9(2):866-71. PubMed ID: 12576461
    [Abstract] [Full Text] [Related]

  • 14. Role of c-myc protein in hormone refractory prostate carcinoma: cellular response to paclitaxel.
    Cassinelli G, Supino R, Zuco V, Lanzi C, Scovassi AI, Semple SC, Zunino F.
    Biochem Pharmacol; 2004 Sep 01; 68(5):923-31. PubMed ID: 15294455
    [Abstract] [Full Text] [Related]

  • 15. CIL-102 interacts with microtubule polymerization and causes mitotic arrest following apoptosis in the human prostate cancer PC-3 cell line.
    Huang YT, Huang DM, Guh JH, Chen IL, Tzeng CC, Teng CM.
    J Biol Chem; 2005 Jan 28; 280(4):2771-9. PubMed ID: 15536083
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G.
    Clin Cancer Res; 2001 May 28; 7(5):1459-65. PubMed ID: 11350918
    [Abstract] [Full Text] [Related]

  • 17. Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin.
    Hu H, Li GX, Wang L, Watts J, Combs GF, Lü J.
    Clin Cancer Res; 2008 Feb 15; 14(4):1150-8. PubMed ID: 18281549
    [Abstract] [Full Text] [Related]

  • 18. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma.
    Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, McConkey DJ, Sweeney P, Radinsky R, Dinney CP.
    Clin Cancer Res; 2000 Dec 15; 6(12):4874-84. PubMed ID: 11156247
    [Abstract] [Full Text] [Related]

  • 19. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
    Cai P, Lu P, Sharom FJ, Fang WS.
    Cancer Lett; 2013 Dec 01; 341(2):214-23. PubMed ID: 23941826
    [Abstract] [Full Text] [Related]

  • 20. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.
    Fox WD, Higgins B, Maiese KM, Drobnjak M, Cordon-Cardo C, Scher HI, Agus DB.
    Clin Cancer Res; 2002 Oct 01; 8(10):3226-31. PubMed ID: 12374693
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.